Inventiva (IVA) AI Stock Analysis

• Market Cap: $616.04M
• Dividend Yield: N/A
• Average Volume (3M): 99.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: -12.52%
• EPS Growth: -82.84%
• Country: US
• Employees: 114
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.62
• Shares Outstanding: 145,951,280
• 10 Day Avg. Volume: 175,727
• 30 Day Avg. Volume: 99,378
• PEG Ratio: -0.01
• Price to Book (P/B): -1.01
• Price to Sales (P/S): 11.68
• P/FCF Ratio: -1.25
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 29.46
• Enterprise Value/Gross Profit: 29.46
• Enterprise Value/Ebitda: -1.63
• 1Y Price Target: $18.14
• Price Target Upside: 342.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $4.00 ▼(-2.44% Downside)

Inventiva's overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.

Positive Factors

Strategic Leadership Change

The appointment of Andrew Obenshain as CEO is a strategic move to enhance U.S. market expansion. His experience in drug approvals and commercialization is expected to strengthen Inventiva's position in the MASH field, potentially driving long-term growth and market presence.

R&D Investment

The $100 million ATM program aims to finance R&D for lanifibranor and other projects. This investment supports ongoing clinical trials and strengthens Inventiva's financial position, potentially enhancing its competitive edge in the biotechnology sector.

Revenue Growth

The substantial revenue growth indicates successful product development partnerships and licensing agreements. This trend, if sustained, could improve financial stability and support long-term strategic goals.

Negative Factors

Financial Instability

Negative stockholders' equity and high liabilities indicate financial distress, limiting Inventiva's ability to invest in growth opportunities and posing risks to its long-term sustainability.

Cash Flow Challenges

Negative cash flows suggest Inventiva is not generating sufficient cash from operations, which may hinder its ability to fund R&D and other strategic initiatives, impacting long-term viability.

Profitability Issues

Ongoing losses and negative margins reflect operational inefficiencies. This persistent lack of profitability could strain resources and limit the company's capacity to achieve sustainable growth.

Inventiva Business Overview & Revenue Model

Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

How the Company Makes Money

Inventiva generates revenue through a combination of product development partnerships, licensing agreements, and potential milestone payments from its collaborations with larger pharmaceutical companies. The company typically enters into strategic alliances that allow it to share the costs and risks associated with drug development while also receiving upfront payments and royalties based on the sales of partnered products. Additionally, Inventiva may receive funding through grants and public financing aimed at supporting research in rare diseases and metabolic disorders, contributing to its financial sustainability.

Inventiva Financial Statement Overview

Summary

Inventiva is facing substantial financial difficulties with persistent losses, negative margins, and significant reliance on external financing. The income statement, balance sheet, and cash flow statement all indicate financial distress, with negative equity and poor cash flow generation.

Income Statement

Inventiva's income statement highlights significant challenges in profitability. The company reports consistent negative net income and EBIT over the years. The revenue growth rate is volatile, with a decrease in the most recent year. Both gross profit and net profit margins are negative, indicating that the company is struggling to cover its costs. EBITDA margin is also highly negative, showcasing operational inefficiencies.

Balance Sheet

Inventiva's balance sheet reveals financial instability with negative stockholders' equity and a high total liabilities figure. The debt-to-equity ratio is not applicable due to negative equity, and return on equity is also negative, reflecting poor returns on shareholders' investments. The equity ratio is negative, further indicating financial distress and a reliance on liabilities.

Cash Flow

The cash flow statement indicates persistent negative operating and free cash flows, suggesting that Inventiva is not generating enough cash from its operations to sustain its business activities. While there is a significant financing cash flow, likely from debt or equity raises, the operating cash flow to net income ratio and free cash flow to net income ratio are weak, pointing towards cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.20M	17.48M	12.18M	4.19M	372.00K
Gross Profit	9.20M	17.50M	17.06M	4.19M	4.42M
EBITDA	-166.53M	-102.04M	-56.29M	-52.76M	-31.77M
Net Income	-184.21M	-110.43M	-54.27M	-49.64M	-33.62M
Balance Sheet
Total Assets	118.97M	69.56M	116.00M	121.98M	138.92M
Cash, Cash Equivalents and Short-Term Investments	96.56M	27.34M	87.78M	86.55M	113.02M
Total Debt	54.33M	37.49M	34.51M	10.12M	10.06M
Total Liabilities	225.61M	101.59M	70.53M	33.12M	27.71M
Stockholders Equity	-106.65M	-32.03M	45.48M	88.87M	111.21M
Cash Flow
Free Cash Flow	-86.26M	-82.15M	-45.49M	-48.16M	-30.88M
Operating Cash Flow	-85.93M	-81.61M	-44.93M	-47.63M	-30.59M
Investing Cash Flow	8.74M	-7.73M	8.87M	-1.79M	-8.56M
Financing Cash Flow	145.59M	29.08M	37.27M	25.45M	111.67M

Inventiva Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVA, the sentiment is Negative. The current price of 4.1 is below the 20-day moving average (MA) of 4.91, below the 50-day MA of 5.40, and above the 200-day MA of 3.79, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 41.11 is Neutral, neither overbought nor oversold. The STOCH value of 7.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVA.

Inventiva Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
URGN	50 Neutral	$916.49M	―	―	―	10.85%	-1.41%
KURA	47 Neutral	$866.69M	―	-65.10%	―	―	-5.18%
MRVI	46 Neutral	$732.89M	―	-55.41%	―	-22.52%	-37.00%
IOVA	45 Neutral	$658.57M	―	-53.16%	―	636.99%	27.10%
IVA	41 Neutral	$616.04M	-0.99	―	―	-12.52%	-82.84%
MBX	38 Underperform	$922.03M	―	-56.28%	―	―	―

Inventiva Corporate Events

Inventiva Announces General Meeting to Discuss Strategic Resolutions

On October 20, 2025, Inventiva S.A. announced the upcoming Ordinary and Extraordinary General Meeting scheduled for November 27, 2025, in Paris, France. The meeting will address several key agenda items, including the approval of the CEO’s compensation policy, a settlement agreement with Mr. Frédéric Cren, and the authorization for the Board to grant share options. These resolutions reflect Inventiva’s strategic focus on aligning executive compensation with company performance and expanding its capital structure to support future growth, potentially impacting shareholder value and employee incentives.

Inventiva Launches $100 Million ATM Program to Boost R&D Efforts

On October 14, 2025, Inventiva announced the implementation of a new At-The-Market (ATM) program, filing a shelf registration statement with the SEC to issue and sell ordinary shares in the form of American Depositary Shares (ADS) for up to $100 million. The proceeds are intended to finance the research and development of lanifibranor, working capital requirements, and general corporate purposes. The ATM program allows for sales to eligible investors, with the new shares to be traded on Euronext Paris and Nasdaq. This strategic move aims to strengthen Inventiva’s financial position and support its ongoing clinical trials, potentially impacting its market positioning and stakeholder interests.

Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion

On October 1, 2025, Inventiva announced the appointment of Andrew Obenshain as the new Chief Executive Officer, succeeding co-founder Frédéric Cren. This leadership change is part of a strategic move to support Inventiva’s growth, particularly in preparing for potential commercialization in the U.S. market for MASH. Obenshain’s global experience in drug approvals and commercialization is expected to strengthen Inventiva’s position in the MASH field and advance the development of lanifibranor, a promising oral therapy for MASH.

Inventiva S.A. Reports Significant Revenue Growth Amid Rising Losses

On September 29, 2025, Inventiva S.A. released its unaudited financial results for the first half of 2025, revealing a significant increase in revenues to €4,454,000 from €41,000 in the same period last year. Despite this revenue growth, the company reported a net loss of €175,882,000, which is a substantial increase from the previous year’s loss of €49,029,000. The financial update highlights the company’s ongoing challenges in managing its expenses, particularly in research and development and general administrative costs, which have impacted its financial performance.